Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > New tranche of went thru

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon May 05, 2022 2:06pm

83 Views

Post# 34659471

RE:RE:RE:RE:RE:RE:RE:New tranche of went thru

You don't need to be a brain surgeon to see the ups and downs of shares held by these Directors over time. The only people that seem to be making money off this company are the Directors and Insiders.
It certainly is not the regular shareholders.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter